Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Anemia Clinical Trial

Official title:

A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05237713
• Other study ID #: CANFIRE
• Status: Terminated
• Phase: Phase 2
• Start date: April 26, 2022
• Est. completion date: February 29, 2024

Study information

• Verified date: May 2024
• Source: University of Leipzig
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.

Description:

To study the erythroid response rate (HI-E) of canakinumab in patients with IPSS-R very low, low, or intermediate risk MDS or MDS/MPN after 6 months of treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: February 29, 2024
• Est. primary completion date: February 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of

1. Lower-risk myelodysplastic syndrome (MDS) OR

2. Myelodysplastic/myeloproliferative neoplasm (MDS/MPN) including MDS/MPN-RS-T, MDS/MPNu, aCML, or CMML (as per the World Health Organization [WHO] 2016 classification) Note: Diagnoses will be confirmed by central morphological review during screening assessment

2. Very low, low or intermediate risk disease MDS with up to 3.5 points according to the revised International Prognostic Scoring System (IPSS-R) classification (to be confirmed during screening assessment). For MDS/MPN < 10% bone marrow blasts at screening. For CMML low or intermediate risk according to CMML-Specific Prognostic Scoring System (CPSS Score).

3. Symptomatic anemia (all NTD, LTB, or HTB): has to be documented in the 16 weeksbaseline period ending on the day of inclusion. Patients should be registered only if it is expected at time of registration that

1. a valid and complete hemoglobin and transfusion history will be available at inclusion AND

2. the hemoglobin mean over the baseline period will be less than 10 g/dL OR three or more RBC-transfusions will have been given during the baseline period documenting transfusion dependence.

4. Documented transfusion strategy: A transfusion trigger threshold is needed which characterizes the transfusion strategy - ideally for the whole baseline period, but at least for the time from registration to the end of the study.

5. Relapsed / refractory / intolerant / ineligible (endogenous serum erythropoietin levels = 200 U/L) to ESA treatment

6. Age = 18 years

7. Written informed consent Exclusion Criteria: Patients meeting any of the following exclusion criteria are not to be enrolled in the trial. Compliance with major study procedures

1. Patient does not accept bone marrow sampling during screening and treatment period.

2. Patient does not accept peripheral blood sampling for screening and during treatment.

3. Patient does not accept subcutaneous application of canakinumab every three weeks Contraindications

4. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding a. iron deficiency must be determined by calculated transferrin saturation (iron/total iron binding capacity) = 20%, or serum ferritin = 15 µg/L

5. Prior allogeneic or autologous stem cell transplant

6. Known history of diagnosis of AML Safety

7. Severe neutropenia defined by ANC = 0.5 Gpt/l

8. Severe thrombocytopenia with platelets (PLT) < 30 Gpt/L

9. Serum creatinine > 1.5x ULN OR measured or calculated creatinine clearance < 40 ml/min (NOTE: creatinine clearance should be calculated per institutional standard. GFR can also be used)

10. Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) or alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT) = 3.0 x upper limit of normal (ULN) - both have to be measured

11. Eastern Cooperative Oncology Group (ECOG) > 2

12. Total bilirubin = 2.0 x ULN

1. higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (ie, ineffective erythropoiesis).

2. subjects are excluded if there is evidence of autoimmune hemolytic anemia manifested as a corrected reticulocyte count of > 2% with either a positive Coombs' test or over 50% indirect bilirubin

13. Active second malignancy at time of study entry

14. Prior history of malignancies, other than MDS, unless the subject has been free of the disease for = 5 years. However, subjects with the following history/concurrent

conditions are allowed:

1. Basal or squamous cell carcinoma of the skin

2. Carcinoma in situ of the cervix

3. Carcinoma in situ of the breast

4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)

15. Major surgery within 8 weeks prior to screening (NOTE: Subjects must have completely recovered from any previous surgery prior to inclusion)

16. Myocardial infarction, uncontrolled angina, uncontrolled heart failure, or uncontrolled cardiac arrhythmia within 6 months prior to screening

17. Positive test result as an indicator for active or latent tuberculosis (evaluation performed per local treatment guidelines or clinical practice)

18. Subjects with suspected or proven immunocompromised state or infections, including:

1. Known history of testing positive for Human Immunodeficiency Virus (HIV) infections.

2. Known active or recurrent, hepatitis B and C (positive or indeterminate laboratory results).

3. Those with any other medical condition such as active infection, treated or untreated, which in the opinion of the investigator places the subject at an unacceptable risk for participation in immunomodulatory therapy.

4. Those requiring systemic or local treatment with any immune modulating agent in doses with systemic effects e.g.: Prednisone >20 mg (or equivalent) oral or intravenous daily for >14 days; Prednisone > 5 mg and = 20 mg (or equivalent) daily for > 30 days; Equivalent dose of methotrexate >15 mg weekly.

5. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product (see Investigator´s Brochure). Excluded treatments before and during study treatment

19. Anticancer cytotoxic chemotherapeutic agent or treatment for at least 14 days prior to registration and during study treatment

20. Corticosteroids or other immunosuppressive therapies (TNF-Blocker, other IL-1 Blocking Agent, Disease-modifying anti-rheumatic drugs (DMARDs) including ciclosporin, cyclophosphamide, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, sulfasalazine) for at least 14 days prior to registration and during study treatment

21. Treatment with ESAs, luspatercept, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) for at least 14 days prior to registration and during study treatment

22. Treatment with disease modifying agents (eg, immune-modulatory drugs [IMiDs such as lenalidomide, hypomethylating agents] or experimental agents for underlying MDS disease for at least 14 days prior to registration and during study treatment

23. Prior treatment with canakinumab

24. Live vaccination during study treatment Special considerations for females

25. Pregnant or breastfeeding females

26. Positive pregnancy test in women of childbearing potential NOTE: Urine or serum pregnancy test should be repeated within 3 days prior to receiving study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required additionally

27. Female subjects of childbearing potential unwilling to use an adequate method of contraception for the course of the study through 90 days after the last dose of study medication NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject Special considerations for males

28. Male subjects with procreative capacity not willing to use an adequate method of contraception, starting with the first dose of study therapy through 90 days after the last dose of study therapy NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject Regulatory requirements

29. Participation in other interventional trials

30. Patients under legal supervision or guardianship

Related Conditions & MeSH terms

• Anemia
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• Canakinumab Injection
Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years

Locations

Country	Name	City	State
Germany	Medizinisches Versorgungszentrum "Onkologischer Schwerpunkt am Oskar- Helene-Heim"	Berlin
Germany	Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Medizinischen Klinik und Poliklinik I / Hämatologie	Dresden
Germany	Klinik und Poliklinik für Hämatologie und Zelltherapie, Hämostaseologie	Leipzig

Sponsors (2)

Lead Sponsor	Collaborator
University of Leipzig	Novartis Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HI-E after 6 months of treatment	Erythroid response rate (HI-E) of canakinumab	6 months
Secondary	HI-E response duration	Duration of erythroid response rate will be measured up to loss of response or reaching end of study (after max. 3 years of treatment)	up to three years
Secondary	Number of (serious) adverse events	The safety profile of canakinumab will be described by collecting AE (adverse event) and SAE (serious adverse event) information up to the start of new treatment or reaching end of study (after max. 3 years of treatment). Special consideration will be laid on events that lead to treatment discontinuation.	up to three years
Secondary	Disease progression	Proportion of disease progression (after reaching PD at any time during the trial after primary end-point visit)	after 24 weeks
Secondary	Impact of canakinumab on quality of life by using the validated Quality of Life in Myelodysplasia Scale (QUALMS)	QoL assessment using the QUALMS questionnaire up to end of treatment: 38-item assessment tool for patients with Myelodysplastic Syndromes (MDS) QUALMS scores ranged from 24 to 99, with higher scores for better outcome	From the date of treatment start until the end of study, assessed up to 36 months
Secondary	Impact of canakinumab on quality of life by using the validated European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30)	QoL assessment using the EORTC-C30 questionnaire up to end of treatment: To assess patient-reported quality of life during canakinumab treatment: 30 questions assessing the quality of life of oncology patients across 10 subscales will be analyzed. All subscales have a score range from 0 to 100 points.; Function subscales: a higher score represents a higher quality of life. Symptoms subscales: higher score represents higher level of symptoms/problems, i.e., represents lower quality of life	From the date of treatment start until the end of study, assessed up to 36 months